75N93023C00001↗
Microbiotix, Inc. received this contract from National Institutes of Health Niaid, National Institutes of Health: $8.80M obligated so far for health r&d services; health care services; applied research. It runs to 2028-03-01.
Key facts · data as of Oct 25, 2026
- Recipient
- Microbiotix, Inc.
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Obligated to date
- $8.80M
- Potential value
- $14.20M
- Ends
- 2028-03-01
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 75N93023C00001, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_75N93023C00001_7529_-NONE-_-NONE-
Microbiotix, Inc.: all federal awards · Department of Health and Human Services: spending · National Institutes of Health Niaid: what it buys · The follow-on: recompete brief
TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES.
Up for re-bid: ends 2028-03-01. Recompete brief → · 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases ↗
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Competition
- Full and open competition · 10 offers received
- Pricing
- Cost plus fixed fee
- How it was bought
- Standalone contract
- Solicitation
- BAA2022-1
- Where the work is
- Worcester, MA · district MA-02
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
6 actions since 2022-10-31. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-21 | P00005 | Option exercised | $3.79M | EO14398 TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. |
| 2026-07-09 | P00004 | Administrative change | $0 | EO14398 TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. |
| 2025-08-19 | P00003 | Option exercised | $2.94M | TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. |
| 2024-10-10 | P00002 | Administrative change | $0 | TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. |
| 2023-09-26 | P00001 | Administrative change | $0 | TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. |
| 2022-10-31 | 0 | $2.07M | TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗